Physician profile
James G Freeman
NPI 1104862986
$3,247.15
in general payments reported to CMS, 2019-2025
24 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $141 · 2021: $226 · 2022: $480 · 2023: $501 · 2024: $637 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.35 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $767.35 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $745.10 | 2019-2025 | |
| Pfizer INC. | $351.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $245.65 | 2019-2025 | |
| Janssen Biotech, INC. | $214.07 | 2019-2025 | Tremfya |
| Ucb, INC. | $138.86 | 2019-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $124.90 | 2019-2023 | Taltz, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.78 | 2023 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $67.19 | 2019-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $62.27 | 2019 | |
| Abbott Laboratories | $57.80 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $57.64 | 2019-2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $42.74 | 2020-2023 | Xarelto |
| Sandoz INC. | $40.50 | 2023 | Hyrimoz |
| Celgene Corporation | $38.62 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.43 | 2019-2025 | Actemra |
| Genzyme Corporation | $28.63 | 2019 | |
| Organon LLC | $27.82 | 2023 | Renflexis |
| Merck Sharp & Dohme LLC | $25.73 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.55 | 2019 | |
| Amarin Pharma, INC. | $18.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.